RA
ABVX

Rosalind Advisors’s Abivax ABVX Stock Holding History

Rosalind Advisors’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.78M Buy
+20,869
New +$2.36M 1.03% 20
2024
Q4 		– Sell
-139,983
Closed -$1.61M – 41
2024
Q3 		$1.61M Sell
139,983
-238,433
-63% -$2.86M 1.03% 21
2024
Q2 		$5M Hold
378,416
– – 3.85% 11
2024
Q1 		$5.41M Buy
+378,416
New +$4.88M 5.06% 8

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rosalind Advisors's ABVX Position: Q2 2026 in Review

Rosalind Advisors opened a new position in Abivax (ABVX) in Q2 2026: 20,869 shares worth $2.78M. The stake represents 1.03% of the portfolio and ranks #20 among its holdings. This is a return to the name: Rosalind Advisors previously reported a position in ABVX as recently as Q3 2024.

Rosalind Advisors first reported a position in ABVX in Q1 2024 and has held it in 4 quarters since. The position peaked at $5.41M in Q1 2024. 303 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Rosalind Advisors held 20,869 shares of Abivax worth $2.78M as of Q2 2026.
  • Abivax was a new Rosalind Advisors position in Q2 2026.
  • Abivax made up 1.03% of Rosalind Advisors's portfolio in Q2 2026, its #20 holding.
  • Rosalind Advisors first reported a position in Abivax in Q1 2024 and has held it in 4 quarters since.
  • Rosalind Advisors's Abivax position peaked at $5.41M in Q1 2024.
  • 303 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Rosalind Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.